Kenvue Inc in Consumer Health

April 2024

Kenvue Inc retained its ranking as the second largest company within the consumer health industry after a successful demerger from Johnson & Johnson Inc in May 2023, supported by global power brands like Tylenol, Zyrtec, Imodium and Band-Aid. North America continues to be the company’s main market, but building its portfolio within Asia, Latin America and the Middle East and Africa through Kenvue’s mission of “everyday care” will provide opportunities to expand its consumer footprint.

USD 570
Request More Information

Delivery: 

Files are delivered directly into your account soon after payment is received and any tax certification is verified (where applicable).

This report comes in PPT.

Overview:

Euromonitor International's report on Kenvue Inc delivers a detailed strategic analysis of the company's business, examining its performance in the Consumer Health market and the global economy. Company and market share data provide a detailed look at the financial position of Kenvue Inc, while in-depth qualitative analysis will help you understand the brand strategy and growth prospects of Kenvue Inc.

This report examines:

  • Company share by region and sector
  • Brand portfolio
  • New product developments
  • Marketing and distribution strategies

A detailed SWPT analysis of Kenvue Inc provides strategic intelligence on:

  • Strengths and weaknesses
  • Category and country opportunities for growth
  • Challenges and threats from current competition and future prospects
  • Global and regional market positions

Research you can trust:

Euromonitor International's company profile reports are written by our Consumer Health research team, a dedicated group of analysts that knows the industry inside and out. Buy this report to inform your planning, strategy, marketing, sales and competitor intelligence functions.

Download Table of Contents
Scope
Executive summary
Kenvue is the second largest consumer health company globally
Kenvue’s global footprint
Company overview
Kenvue’s Spin off from Johnson & Johnson opens growth opportunities
US to drive growth due to large brand portfolio and strong pace of innovation
Focused strategy among the leading players to influence performance
Haleon continues to be Kenvue’s main competitor
Kenvue leads in North America, while maintaining a global presence
Top brands Tylenol, Zrytec and Motrin have potential to expand sales in leading markets
Kenvue provides a holistic omnichannel experience to consumers through e-commerce
Kenvue’s launch of the “Everyday Care Mission”
Kenvue innovating by product variety through brands of Tylenol, Motrin and Zarbee’s
Globally Kenvue leads in cough, cold and allergy remedies, followed closely by Haleon
Largest portfolio of products for Kenvue within combination products
Kenvue still the second largest company globally in analgesics
Kenvue’s analgesics portfolio is dominated by systemic analgesics
Product innovation through hybrid product Motrin Dual Action with Tylenol
Kenvue’s digestive remedies portfolio more expansive globally than other categories
Diarrhoeal remedies and indigestion/heartburn remedies dominate Kenvue’s product mix
Overview of consumer health for Kenvue: Product and brand coverage in 2023
Executive summary
Projected company sales: FAQs
Projected company sales: FAQs

Consumer Health

It is the aggregation of OTC, Vitamins and Dietary Supplements (VDS), Sports Nutrition, and Weight Management and Wellbeing

See All of Our Definitions
Share:

Why buy this report:

Gain competitive intelligence about market leaders. Track key industry trends, opportunities and threats. Inform your marketing, brand, strategy and market development, sales and supply functions

NEW REPORT GUARANTEE

If you purchase a report that is updated in the next 60 days, we will send you the new edition and data extraction Free!

© 2024 Euromonitor is privately owned & trademarked. VAT No. GB: 239-2559-40 Registered in England No. 1040587
;